Sichenzia Ross Ference Kesner LLP Represents Laidlaw & Company (UK) Ltd. in $5.2 Million Public Offering
Press Release – New York, NY – May 8, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Laidlaw & Company (UK) Ltd. as sole book-running manager in the underwritten public offering of equity securities of Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). In connection with the offering, Onconova received approximately $5.2 million in gross proceeds from common stock sold at a price to the public of $2.10 per share.
The Sichenzia Ross Ference Kesner LLP team was led by Partners Harvey Kesner and Avital Perlman and associate Evan Berger.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Founding Partner Marc Ross Speaks at Benzinga Cannabis Capital Conference - August 15, 2018
- Founding Partner Gregory Sichenzia Featured in the Media Discussing Scrutiny of Elon Musk’s Twitter Communications - August 15, 2018
- Founding Partner Gregory Sichenzia Featured on Business Insider Discussing Elon Musk’s Tweets and Securities Legality - August 8, 2018